• ACCRF Grantees

    (Listed by year)

    2016

    Jens Lohr, MD, PhD; Dana Farber Cancer Institute; “Liquid Biomarkers in ACC”
    Nishant Agrawal, MD and Tanguy Seiwart, MD; The University of Chicago Medicine; “Clinical trial correlative studies: PD-1 inhibitor plus chemotherapy”
    Piero Dalerba, MD; Columbia University; “Tumor heterogeneity in ACC”
    Angela Koehler, PhD; Massachusetts Institute of Technology; “Targeting transcription factors in ACC”
    Bhumsuk Keam, PhD; Seoul National University; “Clinical trial correlative studies: axitinib”
    Renata Ferrarotto MD; MD Anderson Cancer Center; “ASCO Career Development Award cofunding: NOTCH-related studies”
    Robert Metcalf MD, PhD; University of Manchester; “Liquid biomarkers in ACC”
    Binbin Li, PhD; Peking University; “ACC Biomarkers and Diagnostics”
    Karl-Heinz Klempnauer, PhD; University of Munster; “Distinguished Researcher Award: MYB”
    Carlos Caulin, PhD; MD Anderson Cancer Center; “Transgenic mouse model for ACC”
    Nikolaus Schultz, PhD; Memorial Sloan Kettering Cancer Center; “ACC Genomic Datasets”
    Anna Keiss, MD, PhD; John Hopkins University; “Targeted Radiopharmaceutical Therapy for ACC”
    Derrick Lin, MD; Massachusetts Eye and Ear Institute/Massachusetts General Hospital; “ACC Tumor Biorepository and Registry”
    Scott Ness, PhD; University of New Mexico; “Screening assay development for ACC”
    Mariana Brait, MSc, PhD; John Hopkins University; “ACC Diagnostics”
    Robert Ramsay, PhD; University of Melbourne; “MYB cDNA vaccine”

    2015

    Arturo Sala, PhD; Brunel University; “Transgenic mouse model for ACC”
    Seema Agarwal, PhD; Georgetown University; “In vivo model for ACC”
    Mary Reyland, PhD and Antonio Jimeno, MD; University of Colorado; “Development of advanced ACC models”
    Silvio Gutkind, PhD; University of California San Diego; and Lars Engelhorn, PhD, University of Copenhagen; “Modeling ACC progression and targeted therapies”
    Jon Aster, MD, PhD; Brigham and Women’s Hospital; “NOTCH1 sequencing in ACC”
    Bradley Bernstein, MD, PhD; Massachusetts General Hospital; “Targeting MYB and epigenetic factors in ACC”
    Len Zon, MD; Harvard Stem Cell Institute/Boston’s Children Hospital; “Screening for MYB inhibitors in zebrafish”

    2014

    Arturo Sala, PhD; Brunel University; “Generating the MYB-NFIB fusion in vitro”
    Jon Aster, MD, PhD; Brigham and Women’s Hospital; “Biomarkers in ACC”
    Sergey Ivanov, PhD; Yale University; “Targeting cancer stem cells in ACC”
    Arturo Sala, PhD; Brunel University; “Assessing MYB-NFIB oncogenic potential in vitro”
    Joan Robbins, PhD; Tocagen; “Biomarkers of ACC infectability”
    Britta Weigelt, PhD, and Jorge Reis-FIlho, MD, PhD; Memorial Sloan Kettering Cancer Center; “Characterization of MYB-NFIB in ACC of the breast”
    Marc Pusztaszeri, MD; Geneva University Hospital; and William Faquin, MD, PhD; Massachusetts Eye and Ear Infirmary; “ACC Diagnostics”
    Karl-Heinz Klempnauer, PhD; University of Munster; “Development and screening assays for MYB inhibitors”
    Jon Aster, MD, PhD; Brigham and Women’s Hospital; “ACC Diagnostics”
    Rogerio Castilho, DDS, MS, PhD; University of Michigan; “Targeting ACC initiating cells”
    Adi Gazdar, MD; University of Texas Southwestern; “ACC cell lines”
    Frederic Kaye, MD; University of Florida; “ACC cell lines”
    Jon Schoenfeld, MD, MPhil, MPH; Dana Farber Cancer Institute; “Immunological markers in ACC”
    Seema Agarwal, PhD; Georgetown University; “ACC model systems”
    Christopher Moskaluk, MD, PhD; University of Virginia; “MYB co-factors in ACC”

    2013

    Robert Ramsay, PhD and Goran Stenman, DMD, PhD; University of Melbourne and University of Gothenburg; “MYB-NFIB fusion mechanism of action in ACC”
    Patrick Ha, MD and Nishant Agarwal, MD; John Hopkins University, “ACC sequencing study”
    John Bushweller, PhD; University of Virginia; “Screening for MYB inhibitors”
    Richard Bakst, MD; Mount Sinai; “Perineural spread in ACC”
    Joan Robbins, PhD; Tocagen; “ACC infectability studies”
    Tan Ince, MD, PhD; University of Miami; “ACC cell lines”
    Michael Barrett, PhD; TGen; “Clinical trial correlative studies: vorinostat”
    Timothy Chan, MD, PhD; Memorial Sloan Kettering Cancer Center; “ACC sequencing study”
    Kwok Wong, MD, PhD; Dana Farber Cancer Institute; “MYB-NFIB genetically engineered mouse model”
    Marc Pusztaszeri, MD; Geneva University Hospital; and William Faquin, MD, PhD; Massachusetts Eye and Ear Infirmary; “ACC Diagnostics”

    2012

    Scott Ness, PhD; University of New Mexico; “MYB Conference”
    Tom Gonda, PhD; University of Queensland; “In vivo models in ACC”
    Goran Stenman, DMD, PhD; University of Gothenburg; “1p deletions and receptor tyrosine kinases in ACC”
    Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “Biobanking, Model Development and Genomics”

    2011

    Margaret Brandwein-Gensler, MD; University of Alabama, Birmingham; “HPV and ACC”
    Kwok Wong, MD, PhD; Dana Farber Cancer Institute; “MYB-NFIB genetically engineered mouse model”
    Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “Biobanking, Model Development and Genomics”
    Wendell Yarbrough, MD, MMHC; Yale University; “TRKC and neurotrophic signaling in ACC”
    Scott Ness, PhD; University of New Mexico; “c-MYB variant activity in ACC”
    Bradley Bernstein, MD, PhD; Massachusetts General Hospital; “Role of MYB translocation on chromatin landscape in ACC”
    Len Zon, MD; Harvard Stem Cell Institute/Boston’s Children Hospital; “Screening for MYB inhibitors in zebrafish”
    Lurdes Queimado, MD, PhD; University of Oklahoma; “ACC cell lines”
    Jaques Nor, DDS, MS, PhD; University of Michigan; “Stem cells in ACC”

    2010

    Patrick Ha, MD; John Hopkins University, “Tumor suppressor screen In ACC PDXs”
    Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “Genomic analysis in ACC”
    Timothy Bender, MS, PhD; University of Virginia; “MYB-NFIB fusion proteins in ACC”
    Tan Ince, MD, PhD; University of Miami; “ACC cell lines”
    Pat LoRusso, DO; Karmanos; “Clinical trial correlative studies: vorinostat”
    Christopher Moskaluk, MD, PhD; University of Virginia; “ACC disease pathway analysis”
    Andrew Futreal, PhD; Wellcome Trust Sanger Institute; “ACC genomics”
    Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “MYB-NFIB fusion gene and screening of ACC”

    2009

    Goran Stenman, DMD, PhD; University of Gothenburg; “Novel fusions in ACC”
    Jason Papin, PhD; University of Virginia; “Bioinformatics systems biology approach to ACC”
    Andrew Futreal, PhD; Sanger Institute; “ACC rearrangements”

    2008

    Mike Rothenburg, MD; Massachusetts General Hospital; “Model development and characterization”
    National Institute of Dental and Craniofacial Research; “Salivary Gland Tumor Research: Biorepository and RDCRN”
    Mary Pat Moyer, PhD; INCELL; “ACC cell lines”
    Patrick Ha, MD; John Hopkins University, “ACC cell lines from PDXs”
    John Basile, DDS, DMSc; University of Maryland; “Perineural invasion in ACC”
    Claudia Kirsch, MD; University of California, Los Angeles; “3T MRIs and radiologic differentiation in ACC”
    Naishuo Zhu, MD, PhD; Fudan University; “Metastasis-related gene function in ACC”
    Ed Harlow, PhD; Harvard University; “Genomic screens in ACC”

    2007

    National Disease Research Interchange; “Rare Disease Biospecimen Alliance”
    Andrew Futreal, PhD; Sanger Institute; “ACC sequencing pilot”
    Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “Biobanking and model development”

    2006

    Goran Stenman, DMD, PhD; University of Gothenburg; “Genomic imbalances in ACC”

    2005

    Christopher Moskaluk, MD, PhD; University of Virginia; “Biobanking and model development”